Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX)

Sector: Healthcare Industry: Biotechnology CIK: 0001581178
P/B 2.33
P/E -7.12
P/S 0.00
Market Cap 209.59 Mn
ROIC (Qtr) -52.75
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 170,603.00
Debt/Equity (Qtr) 0.00

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 88.96M provide 1168.43x coverage of short-term debt 76136, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 92.35M provides 541.31x coverage of total debt 170603, indicating robust asset backing and low credit risk.
  • Cash position of 88.96M provides exceptional 2078x coverage of minority interest expenses 42810, indicating strong liquidity.
  • Cash reserves of 88.96M provide robust 23.34x coverage of current liabilities 3.81M, indicating strong short-term solvency.
  • Cash position of 88.96M represents healthy 1.02x of working capital 87.59M, demonstrating strong operational liquidity.

Cons

  • Investment activities of (439403) provide weak support for R&D spending of 17.35M, which is -0.03x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (24.80M) shows concerning coverage of stock compensation expenses of 4.08M, with a -6.07 ratio indicating potential earnings quality issues.
  • Free cash flow of (25.24M) provides weak coverage of capital expenditures of 439403, with a -57.43 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (29.41M) show weak coverage of depreciation charges of 219423, with a -134.02 ratio indicating high capital intensity and potential reinvestment needs.
  • Operating cash flow of (24.80M) provides minimal -2594.94x coverage of tax expenses of 9556, suggesting potential tax planning inefficiencies or unsustainable tax positions.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 2.06 12.31
EV to Cash from Ops. -7.66 23.25
EV to Debt 1,112.89 738.44
EV to EBIT -6.46 -9.16
EV to EBITDA -6.43 6.95
EV to Free Cash Flow [EV/FCF] -7.52 21.90
EV to Market Cap 0.91 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 2.33 22.34
Price to Earnings [P/E] -7.12 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage -214,649.38 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -443.90 -27.13
Cash and Equivalents Growth (1y) % 927.03 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -5.21 -46.93
EBITDA Growth (1y) % 5.77 -1.68
EBIT Growth (1y) % -5.31 -56.45
EBT Growth (1y) % -2.17 -12.70
EPS Growth (1y) % 6.38 -28.31
FCF Growth (1y) % 16.07 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 23.34 3.85
Current Ratio 23.98 7.27
Debt to Equity Ratio 0.00 0.40
Interest Cover Ratio -214,649.38 841.00
Times Interest Earned -214,649.38 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22